Innovation in vision

New Medicines in Ophthalmology

Our Company

We are a pre-clinical stage ophthalmology company developing our new mechanism of action medicines for corneal surgeries and chronic retinal conditions

Our Science

Our new mechanism immunomodulatory drugs delivered by SmartCelle target pain and inflammation at the front and back of the eye

Our Indications

SmartCelle TA-A001 addresses the severe pain of keratoconus surgery, PRK and Cataract removal

Glaucoma, dry-eye and retinal diseases are also in our sights


Phone: 514 883 3447



TALLC issues new Corporate Presentation

Dr. Damon Smith at Biotech Show Case

TALLC at the Ophthalmology Innovation Summit

TALLC Corporation Announces Grant of New SmartCelle Patent for Enhanced Ocular Delivery of TA-A001

Tetra Bio-Pharma and Altus Formulation Form New Company “TALLC” to Exploit TA-A001

TALLC and IACTA to present at the H.C. Wainwright Bioconnect Conference: January 10-13, 2022

TALLC will present details of the SmartCelle insoluble drug delivery platform for ocular, parenteral and oral delivery and an update on t…

Load More...
TALLC Innovation in Vision

© TALLC Inc. 2020